KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in <i>BRAF</i>-mutant melanoma
Pier Francesco Ferrucci(MultiMedica), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Razi Ghori(Merck & Co., Inc., Rahway, NJ, USA (United States)), Inge Marie Svane(Copenhagen University Hospital), Rosalie Stephens(Auckland City Hospital), Eduard Gasal, Henrik Schmidt(Aarhus University Hospital), Georgina V. Long(The University of Sydney), Paola Queirolo, Scott J. Diede(Merck & Co., Inc., Rahway, NJ, USA (United States)), Michal Lotem(Hadassah Medical Center), Mahmoud Abu-Amna(Emek Medical Center), Antoni Ribas(University of California, Los Angeles), Elizabeth Croydon(Merck & Co., Inc., Rahway, NJ, USA (United States)), Anna Maria Di Giacomo(University of Siena), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Victoria Atkinson(Greenslopes Private Hospital), Jacob Schachter
Cited by 178
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
|Journal of Clinical Investigation|2017|3.9k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k